Abstract
ObjectiveTo evaluate the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have